4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease

Journal of Medicinal Chemistry

Volumn 40, Issue 23, 1997, Pages 3781-3792

  D tait, Bradley ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(2 TERT BUTYL 5 METHYLPHENYL)SULFANYL] 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 (2 PHENYLETHYL) 2H PYRAN 2 ONE; 5 [3,6 DIHYDRO 4 HYDROXY 6 OXO 2 PHENYL 5 (2 PHENYLETHYLTHIO) 2H PYRAN 2 YL]PENTANOIC ACID; 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 3 [(2 PHENYLETHYL)THIO] 2H PYRAN 2 ONE; 5,6 DIHYDRO 4 HYDROXY 6 PHENYL 6 (2 PHENYLETHYL) 3 [(2 PHENYLETHYL)THIO] 2H PYRAN 2 ONE; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTI-HIV AGENTS; BINDING SITES; COUMARINS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; PYRONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9844223910     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970615f     Document Type: Article

References (39)

1. Wakefield, J. K.; Morrow, C.D.; Park, J. Viral Gene Products and Replication of the Human Immunodeficiency Type 1 Virus. Am J. Physlol. 1994,266 (Cell Physiol. 35), C1135 and references therein.
2. Katz, R. A.; Skalka, A.M. The Retroviral Enzymes. Annu. Rev. Biochem. 1994, 63, 133-173.
3. Redshaw, S. Inhibitors of HIV Proteinase.Exp. Opin. Invest. Drugs 1994, 3 (3), 273-286.
4. Kohl, N. E.; Scolnick, E.M.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acad. Sci USA. 1988, 85, 4686-4690 and references therein.
5. (a) Meek, T. D.Inhibitors of HIV-1 Pjotease. J. Enzyme Inhib. 1992, 6, 65-98. (b) Thaisrivongs, S. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1994, 17, 133-144, Chapter 14.
6. (a) First HIV Protease Inhibitor Approved by FDA. Antiviral Agents Bull. 1995, 8 (12), 353-355.
7. (b) Moyle, G.; Gazzard, B.Current Knowledge and Future Prospects for the Use of HFV Protease Inhibitors. Drugs 1996, 5, 701-712.
8. (a) Askin, D.; Eng, K.K; Rossen, K.; Purick, R. M.; Wells, K. M.; Volante, R. P.; Reider, P. J. Highly Diastereoselective Reaction of a Chiral, Non-racemic Amide Enolate with (S)-glycidyl tosylate. Synthesis of the Orally Active HIV-1 Protease Inhibitor L-735,524. Tetrahedron Lett. 1994, 35, 673-676.
9. (b) Parkes, K. E. B.; Bushnell, D. J.; Crackett, P. H.; Dunsdon, S. J.; Freeman, A. C.; Gunn, M. P.; Hopkins, R. A.; Lambert, R. W.; Martin, J. A.; Merrett, J. H.; Redshaw, S.; Spurden, W. C.; Thomas, G. J. Studies Toward the Large-scale Synthesis of the HIV Protease Inhibitor Ro 31-8959. J. Org. Chem. 1994, 59, 3656-3664
10. Vella, S. Update on a Proteinase Inhibitor. AIDS 1994, 8 (Suppl. 3), S25-229.
11. (a) Mascolini, M. J.Int. Assoc. Physicians AIDS Care 1995,11-29. (b) Reference 6b.
12. Tait, B. D.; Domagala, J.; Ellsworth, E.L.; Ferguson, D.; Gajda, C.; Hupe, D.; Lunney, E. A.; Tummino, P. J. Inhibitors of HIV Protease: Unique Non-peptide Active Site Templates. J. Mol. Recogn. 1996, 9, 139-142.
13. (a) Tummino, P. J.; Vara Prasad, J.V. N.; Ferguson, D.; Nouhan, C.; Graham, N.; Domagala, J. M.; Ellsworth, E.; Gajda, C.; Hagen, S. E.; Lunney, E. A.; Para, K. S.; Tait, B. D.; Pavlovsky, A.; Erickson, J. W.; Gracheck, S.; McQuade, T. J.; Hupe, D. J. Discovery and Optimization of Nonpeptide HIV-1 Protease Inhibitors. Bioorg. Med. Chem. 1996,4,1401-1410.
14. (b) Hamilton, H.; Tait, B. D.; Gajda, C.; Hagen, S.; Ferguson, D.; Lunney, E.; Pavlovsky, A.; Tummino, P. 6-Phenyl-6-alkylamido-5,6-dihydropyrone-2H-pyran-2-ones: Novel HIV Protease Inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 719-724.
15. (a) Romines, K. R.; Morris, J.K.; Howe, W. J.; Tomich, P. K.; Horng, M.-M.; Chong, K.-T.; Hinshaw, R. R.; Anderson, D. J.; Strohbach, J. W.; Turner, S. R.; Mizsak, S. A. Cycloalkylpyranoncs and Cycloalkyldihydropyrones as HFV Protease Inhibitors: Exploring the Impact of Ring Size on Structure-Activity Relationships. J. Med. Chem. 1996, 39, 4125-4130.
16. (b) Thaisrivongs, S.; Skulnick, H. I.; Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Johnson, P. D.; Aristoff, P. A.; Judge, T. M.; Gammill, R. B.; Morris, J. K.; Romines, K. R.; Chrusciel, R. A.; Hinshaw, R. R.; Chong, K.-T.; Tarpley, W. G.; Poppe, S. M.; Slade, D. E.; Lynn, J. C.; Homg, M.-M.; Tomich, P. K.; Seest, E. P.-, Dolak, L. A.; Howe, W. J.; Howard, G. M.; Schwende, F. J.; Toth, L. N.; Padbury, G. E.; Wilson, G. J.; Shiou, L.; Zipp, G. L.; Wilkinson, K. F.; Rush, B. D.; Ruwart, M. J.; Koeplinger, K. A.; Zhao, Z.; Cole, S.; Zaya, R. M.; Kakuk, T. J.; Janakiraman, M. N.; Watenpaugh, K. D. Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Nonpeptidic Inhibitors. J. Med. Chem. 1996,39, 4349-4353.
17. Thaisrivongs, S.; Romero, D. L.; Tommasi, R. A.; Janakiraman, M. N.; Strohbach, J. W.; Turner, S. R.; Biles, C.; Morge, R. R-; Johnson, P. D.; Aristoff, P. A.; Tomich, P. K; Lynn, J. C.; Horng, M.-M.; Chong, K.-T.; Hinshaw R. R.; Howe, W. J.; Finzel, B. C.; Watenpaugh, K. D. Structure-Based Design of HIV Protease Inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as Effective, Nonpeptidic Inhibitors. J. Med. Chem. 1996, 39, 4630-4642.
18. SYBYL software (Versions 5 and 6) commercially available from Tripos, Inc., 1699 S Hanley Rd, St.Louis, MO 63144.
19. Lunney, E. A.; Hagen, S.E.; Domagala, J. M.; Humblet, C.; Kosinski, J.; Tait, B. D.; Warmus, J. S.; Wilson, M.; Ferguson, D.; Hupe, D.; Tummino, P. J.; Baldwin, E. T.; Bhat, T. N.; Liu, B.; Erickson, J. W. A Novel Nonpeptide HIV-1 Protease Inhibitor: Elucidation of the Binding Mode and its Application in the Design of Related Analogs. J. Med. Chem. 1994,37, 2664-2677.
20. Groutas, W. C.; Huang, T.L.; Stanga, M. A.; Brubaker, M. J.; Moi, M. K. Substituted 2-Pyrones and 5,6-Dihydropyrones as Inhibitors of the Serine Proteases. J. Heterocycl. Chem. 1985, 22, 433-435.
21. Harris, R. F.; Dunbar, J.E. U.S. patent number 3,931,235,1976.
22. Newman, M. S.; Karnes, H.A. The Conversion of Phenols to ThiophenolsViaDialkylthiocarbamates. J. Org. Chem. 1966,37, 3980-3984.
23. Ranasinghe, M. G.; Fuchs, P.L. A Facile Synthesis of Unsymmetrical Thiosulfonates Via Sulfonylation of Mercaptans. Synth. Commun. 1988,18, 227-232.
24. Erickson, J.; Kempf, D.Structure-based Design of Symmetric Inhibitors of HIV-1 Protease. Arch. Virol. 1994, 9, 19-29.
25. Jone deSoIms, S.; Giuliani, E.A.; Guare, J. P.; Vacca, J. P.; Sanders, W. M.; Graham, S. L.; Wiggins, J. M.; Darke, P. L.; Sigal, I. S.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Anderson, P. S.; Huff, J. R. Design and Synthesis of HIV Protease Inhibitors. Variations of the Carboxy Terminus of the HIV Protease Inhibitor L-682,679. J. Med. Chem. 1991, 34, 2852-1857.
26. Ghosh, A.; Thompson, W.; Holloway, M.; McKee, S.; Duong, T.; Lee, H.; Munson, P.; Smith, A.; Wai, J.; Darke, P.; Zugay, J.; Emini, E.; Schleif, W.; Huff, J.; Anderson, P.Potent HIV Protease Inhibitors: The Development of Tetrahydrofuranylglycines as Novel Pa-Ligands and Pyrazine Amides as Ps-Ligands. J. Med. Chem. 1993, 36, 2300-2310.
27. An X-ray cocrystal of 5-[4-hydroxy-5-[(2-isopropyIphenyl)sulfanyl)6-oxo-2-phenyl-3,6-dihydro-2H-pyran- 2-yl]pentanoic acid with HIV-1 was obtained which indicated that the carboxylic acid of the inhibitor is sharing a proton with the Asp 30 side chain.
28. Unpublished results from these labs.
29. Vara Prasad, J. V.N.; Pavlovsky, A.; Para, K. S.; Ellsworth, E. L.; Tummino, P. J.; Nouhan, C.; Ferguson, D. Nonpeptidic HIV Protease Inhibitors: 3-(S-Benzyl substituted)-4-hydroxy-6-(phenyl substituted)-2/f-pyran-2-one with an Inverse Mode of Binding. Bioorg. Med. Chem. Lett. 1996, 6, 1133-1138.
30. Vara Prasad, J. V.N.; Lunney, E. A.; Ferguson, D.; Tummino, P. J.; Rubin, J. R.; Reyner, E. R.; Stewart, B. H.; Guttendorf, R. J.; Domagala, J. M.; Suvorov, L. I.; Gulnik, S. V.; Topol, I. A.; Bhat, T. N.; Erickson, J. W. HIV Protease Inhibitors Possessing a Novel, High-Affinity, and Achiral P1VP2' Ligand with a Unique Pattern of In Vitro Resistance. Importance of a Conformationally-Restricted Template in the Design of Enzyme Inhibitors. J. Am. Chem. Soc. 1995, 117, 11070-11074.
31. Gajda, C.; Tait, B.; Hagen, S.; Tummino, P.; Ferguson, D.; Pavlovsky, A.; Rubin, J.; Lunney, E.Protein Structure-Based Drug Design and Synthesis of Non-peptide HIV Protease Inhibitors. 210thACS National Meeting, Chicago, IL, 1995.
32. Pavlovsky, A.; et al.Unpublished results.
33. Other groups have reported similar binding changes. Reich, S.H.; Melnick, M.; Davies, J. F.; Appelt, K; Lewis, K. K.; Fuhry, M. A.; Pino, M.; Trippe, A. J.; Nguyen, D.; Dawson, H.; VYu, B-W.; Musick, L.; Kosa, M.; Kahil, B.; Webber, S.; Gehlhaar, D. K.; Andrada, D.; Shetty, B. Protein Structure-Based Design of Potent Orally Bioavailable, Nonpeptide Inhibitors of Human Immunodeficiency. Proc. Natl. Acad. Sci. tJ.S-A. 1995,92,3298-3302.
34. Manuscripts in preparation.
35. Tummino, P. J.; Ferguson, D.; Jacobs, C.M.; Tait, B. D.; Hupe, L.; Lunney, E. A.; Hupe, D. Competitive Inhibition of HIV-1
36. Protease by Biphenyl Carboxylic Acids. Arch.Biochem. Biophys. 1995, 316, 523-528.
37. (a) Miyashita, N.; Yoshikoshi, A.; Grieco, P.A. Pyridinium p-toluenesulfonate. A Mild and Efficient Catalyst for the Tetrahydropyranylation of Alcohols. J. Org. Chem. 1977, 42, 23, 3772-3774.
38. (b) Bailey, W. F.; Khanolkar, A. D. Construction of a Sterically Congested Carbon Framework via 5-Hexenyllithium Cyclization. Synthesis of (i)-Cuparene. Tetrahedron 1991,47, 37, 7727-7738.
39. Strubell, V. W.Über Ortho-Metallierungen mit 2-Brom-p-cymol. (Ortho-Metalation of 2-Bromo-p-cymol.) J. Fur Prak. Chem. 1962, 18, 113-116.